Canada has among the highest frequency of people with inflammatory bowel disease (IBD) in the world with over 230,000 cases. IBD is more likely to develop in teens and adults between 15 and 30 years of age and is a lifelong debilitating condition. IBD results from inflammation in the digestive system. The most common symptoms are abdominal pain, diarrhea which may be bloody, weight loss, fatigue and delayed growth and puberty in children. In addition, people with IBD have an increased risk of developing colorectal cancer. Several drugs are available to treat IBD. However, physicians are currently unable to predict which drug would be most effective for a given patient. The objective of this Project is to develop a set of clinical tests that will allow physicians to match an individual IBD patient with the most fitting treatment and will be developing a platform predict responsiveness to any given IBD drug.